Introduction
============

Venous thromboembolism occurs in up to 40% of hospitalized medical and surgical patients in the absence of prophylactic anticoagulation \[[@B1],[@B2]\]. Even with prophylaxis, the risk of venous thromboembolism in critically ill patients approaches 10% and has serious consequences: untreated pulmonary embolism has a mortality rate approaching 25% \[[@B3]-[@B5]\]. Among critically ill patients, those developing venous thromboembolism have longer intensive care unit and hospital stays, longer duration of mechanical ventilation, and higher hospital mortality \[[@B6]\]. Consequently, venous thromboembolism not only is associated with serious morbidity and mortality, but also has major implications for healthcare resource utilization.

Appropriate use of prophylaxis to prevent venous thromboembolism in patients at risk has been identified as one of the most important patient-safety interventions for hospitals \[[@B7]\]. However, substantial variability is found in the use of such prophylaxis in practice. Prevention is most commonly achieved with anticoagulant drugs. Because important decisions about pharmacologic interventions are made with knowledge of their economic consequences, formal economic analyses are useful tools to guide clinicians and policy makers about the value of drug interventions and their consequences \[[@B8],[@B9]\]. However, many evaluations of new drugs do not occur prospectively with efficacy studies, and many are sponsored by the manufacturers, raising the possibility of bias.

We performed a systematic review of economic analyses of venous thromboembolism-prevention strategies in acutely ill hospitalized patients. Our objectives were to review and critically appraise the economic evaluations of a broad spectrum of strategies in diverse patient groups to help inform clinicians and policy makers about the cost-effectiveness of various approaches to venous thromboembolism prophylaxis.

Materials and methods
=====================

Date sources and searches
-------------------------

We searched MEDLINE, EMBASE, the Cochrane Database of Systematic Reviews, ACP Journal Club, Database of Abstracts of Reviews of Effects (DARE), and Cochrane Controlled Trials Register from 1946 to October 21, 2011, by using a combination of the following subject headings and text words: *venous thrombosis, pulmonary embolism, low-molecular-weight heparin, LMWH, dalteparin, enoxaparin, nadroparin, tinzaparin, heparin, unfractionated heparin, UFH, anticoagulants, warfarin, aspirin, fondaparinux, rivaroxaban, dabigatran, intermittent pneumatic compression devices, compression stockings, vena cava filters, venous foot pump, economics, health care cost, cost-effectiveness analysis, cost-benefit analysis*, and *economic analysis*(Additional file [1](#S1){ref-type="supplementary-material"}). No limits regarding publication type were initially applied. To identify additional potentially relevant studies, we checked the reference lists of identified systematic and narrative reviews and the personal files of the authors and collaborators. We also sent the full list of identified articles and inclusion criteria to venous thromboembolism experts in the field to identify additional published or relevant unpublished studies.

Study selection
---------------

From 5,180 potentially relevant citations, 4,816 were excluded based on title and abstract review (Figure [1](#F1){ref-type="fig"}). The full text versions of 89 manuscripts were retrieved for full evaluation. Two reviewers (ST, RF) independently assessed each of the articles and applied the following eligibility criteria: (a) the economic evaluation was based on data from randomized controlled trials or meta-analyses of randomized controlled trials; (b). the study described hospitalized patients; (c) the study compared at least two different venous thromboembolism prophylaxis strategies; (d) the study described drug-acquisition costs, the costs of providing prophylaxis, costs of complications (including venous thromboembolism treatment and prophylaxis failures); and (e) the study described the effect of prophylaxis with respect to the number of venous thromboembolism events prevented and diagnosed. We excluded evaluations based on the following study designs: 1. cohort studies or other observational studies; 2. studies on outpatient use of venous thromboembolism prophylaxis; 3. studies on the treatment of venous thromboembolism; 4. studies examining the efficacy of short-term versus long-term venous thromboembolism prophylaxis; 5. decision analytic models based on data from nonrandomized trials; 6. studies examining anticoagulants for conditions other than venous thromboembolism, and seven letters, editorials, or narrative reviews of economic issues in venous thromboembolism prophylaxis. We also excluded studies appraised as low to moderate quality, as defined later.

![**Study eligibility diagram**.](cc11241-1){#F1}

Data extraction and quality assessment
--------------------------------------

We critically appraised each article by using established criteria \[[@B9]\]. Our goal was to include only those studies that adhered to a high methodologic quality. We assigned an ordinal score of quality based on the criteria set forth in the \"User\'s guide to the medical literature: XIII. How to use an article on economic analysis of clinical practice\" \[[@B9]\]. With a semiquantitative scale incorporating these characteristics, we assigned 1 point for each of the 12 categories. All studies were graded as high (≥ 9 points), medium (5 to 8 points), or low (0 to 4 points) quality by two authors (ST, RF). Disagreements about the inclusion of individual studies were resolved by consensus between two authors (ST, RF). Of the 84 articles selected for full review, 50 were appraised as low or moderate quality, and the remaining 39 studies were selected for data abstraction.

We identified 10 economic evaluations of mechanical prophylaxis, including intermittent pneumatic compression devices, compression stockings, or vena cava filters \[[@B10]-[@B17]\]. None of these articles met our previously stated eligibility criteria.

From each included study, we abstracted the following: the patient group, venous thromboembolism prophylaxis strategy, duration of prophylaxis, time frame of the study, source of the outcome data, source of the cost data, incremental costs and benefits of each strategy, results of any sensitivity analyses, the country in which the study was performed, and the declared source of funding for the economic analysis. We attempted to contact authors of studies for which no external support was declared to ensure that this was the case.

We abstracted the number of thrombotic events, costs, and complication rates of the prophylaxis and of the treatment of venous thromboembolism from each article. We then recorded or calculated the incremental cost-efficacy ratio for each venous thromboembolism prophylaxis strategy. If we were unable to calculate the incremental cost-efficacy ratio because of missing data, we attempted to contact the authors to obtain this ratio or original data. Costs were converted to 2009 US dollars and adjusted for country-specific temporal changes in gross domestic product \[[@B18]-[@B20]\]. We standardized the incremental effects we reported as \"venous thromboembolism events avoided,\" \"life-years or quality adjusted life-years gained\' or \'deaths avoided per 1000 patients\', as is commonly performed in venous thromboembolism literature. We chose in-hospital or near-term (\< 90 days) events for the primary comparisons whenever possible, as the short and longer-term effects of inpatient thromboprophylaxis are often greatest during this time period.

Data synthesis and analysis
---------------------------

Heterogeneity of the interventions, perspectives, and time-horizons precluded meta-analytic techniques to combine incremental cost-efficacy ratios into a single summary statistic. We summarized cost-effectiveness ratios by graphic representation of point estimates on a cost-efficacy plane. Categoric variables and proportions were compared by using the χ^2^or Exact tests as appropriate.

Results
=======

Study comparisons, populations, and format
------------------------------------------

Among the 39 studies included in this review, the following comparisons were made: low-molecular-weight heparins versus placebo (five) \[[@B20]-[@B24]\]; unfractionated heparin versus low-molecular-weight heparins (12) \[[@B21],[@B23]-[@B33]\]; various low-molecular-weight heparins versus warfarin (eight) \[[@B34]-[@B41]\]; various low-molecular-weight heparins compared with one another or other agents (five) \[[@B31],[@B42]-[@B45]\]; fondaparinux versus enoxaparin (11) \[[@B46]-[@B56]\], rivaroxaban versus low-molecular-weight heparins or dabigatran \[[@B57]\], and dabigatran versus low-molecular-weight heparin \[[@B58]\] (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}).

###### 

Study characteristics

  Study characteristics                                         Number of studies
  ------------------------------------------------------------- -------------------
  **Thromboprophylaxis compared**                               
   Low-molecular-weight heparin versus placebo                  5
   Low-molecular-weight heparin versus unfractionated heparin   12
   Low-molecular-weight heparin versus warfarin                 8
   Low-molecular-weight heparin versus fondaparinux             11
   Other                                                        7
  **Patient population**                                        
   Orthopedic surgery                                           26
   Other surgical                                               5
   Medical                                                      8
  **Funding**                                                   
   Industry                                                     25
   Other or unknown                                             14
  **Geographic perspective**                                    
   US                                                           18
   UK                                                           6
   Continental Europe                                           11
   Canada                                                       4

###### 

Study description and quality assessment

  Article             Interventions compared                                                                                                                                                                                                                                      Patient group                                                     Were the outcomes accurately measured?               Were the costs accurately measured?                                      Was uncertainty in analysis determined?                                          Were estimates and costs related to the baseline risk in treatment population?
  ------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------------------ -------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------
  Pechevis, 2000      Enoxaparin 40 mg daily versus placebo for 6-14 days                                                                                                                                                                                                         Medical                                                           Yes; outcomes taken from RCTs                        Yes; data from literature                                                Yes                                                                              Yes
  Lloyd, 2001         UFH 5,000 units twice daily versus enoxaparin 40 mg daily for 6-14 days                                                                                                                                                                                     Medical                                                           Yes; outcomes taken from RCTs                        Yes; data from literature                                                Yes                                                                              Yes
  Lamy, 2002          Enoxaparin 20 mg versus 40 mg versus placebo for 6-14 days                                                                                                                                                                                                  Medical                                                           Yes; outcomes taken from RCTs                        Yes; data from hospital, OHIP                                            Yes                                                                              Yes
  Offord, 2003        Enoxaparin 40 mg daily versus UFH 5,000 units twice daily versus none for 6-14 days                                                                                                                                                                         Medical                                                           Yes; outcomes taken from RCT/meta-analysis           Yes; data from a hospital                                                Yes                                                                              Yes
  Schadlich, 2006     Enoxaparin 40 mg versus UFH 5,000 units three times daily for 6-14 days                                                                                                                                                                                     Medical                                                           Yes; outcomes taken from RCTs/meta-analysis          Yes; data from the German Health System                                  Yes                                                                              Yes
  Drummond, 1994      UFH 5,000 units 3 times daily versus enoxaparin 40 mg daily for 7 days                                                                                                                                                                                      HFS                                                               Yes; outcomes taken from RCTs                        Yes; data from literature                                                Yes                                                                              Yes
  Hawkins, 1997       Enoxaparin 30 mg daily versus UFH 5,000 units for 7 days                                                                                                                                                                                                    THR                                                               Yes; outcomes taken from RCTs                        Yes; data from literature                                                Yes                                                                              Yes
  Marchetti, 1999     UFH 5,000 units twice daily versus LMWH enoxaparin 40 mg daily for 14 days                                                                                                                                                                                  THR                                                               Yes; outcomes taken from RCTs/meta-analysis          Yes; data from literature                                                Yes                                                                              Yes
  McGarry, 2004       UFH 5,000 units twice daily versus enoxaparin 40 mg daily versus nothing for 30 days                                                                                                                                                                        Medical                                                           Yes; outcomes taken from RCTs/meta-analysis          Yes; data from literature                                                Yes                                                                              Yes
  Deitelzweig, 2008   UFH 5,000 units twice daily versus enoxaparin 40 mg daily versus nothing for 5 days                                                                                                                                                                         Medical                                                           Yes; outcomes taken from RCTs                        Yes; data from literature                                                Yes                                                                              Yes
  Wade, 2008          UFH 5,000 units 3 times daily versus dalteparin 5,000 units daily for 10 days                                                                                                                                                                               Gynecology oncology surgery                                       Yes; outcomes taken from RCTs                        Yes; data from literature                                                Yes                                                                              Yes
  Lloyd, 1997         UFH 5,000 units twice daily/3 times daily versus nadroparin for 10-14 days                                                                                                                                                                                  Orthopedic and general surgery                                    Yes; outcomes taken from meta-analysis               Yes; data from published rates of pay, costs from a hospital             Yes                                                                              Yes
  Heerey, 2005        Dalteparin 2,500 units versus 5,000 units versus UFH for 10 days                                                                                                                                                                                            Abdominal surgery                                                 Yes; outcomes taken from RCTs                        Yes; data from Medicare reimbursement                                    Yes                                                                              Yes
  O\'Brien, 1994      Enoxaparin 30 mg twice daily versus warfarin for 7 days                                                                                                                                                                                                     THR                                                               Yes; outcomes taken from RCTs                        Yes; data from literature                                                Yes                                                                              Yes
  Menzin, 1995        Enoxaparin 30 mg twice daily versus warfarin (INR 2-3) versus nothing for 5-14 days                                                                                                                                                                         THR                                                               Yes; outcomes taken from RCTs                        Yes; data from literature                                                Yes                                                                              Yes
  Hull, 1997          Warfarin versus tinzaparin 175 units/kg for 14 days                                                                                                                                                                                                         THR, TKR                                                          Yes; outcomes taken from RCTs                        Yes; data from literature                                                Yes                                                                              Yes
  Hawkins, 1998       Enoxaparin 30 mg twice daily versus warfarin for 10 days                                                                                                                                                                                                    TKR                                                               Yes; outcomes taken from RCTs                        Yes; data from literature                                                Yes                                                                              Yes
  Francis, 1999       Dalteparin 2,500 units, then 5,000 units versus warfarin for 10 days                                                                                                                                                                                        THR                                                               Yes; outcomes taken from RCTs                        Yes; costs from participating hospitals in RCT                           Yes; for costs                                                                   Yes
  Botteman, 2002      Enoxaparin 30 mg daily versus warfarin 5 mg daily for 7 days                                                                                                                                                                                                THR                                                               Yes; outcomes taken from RCTs                        Yes; data from literature                                                Yes                                                                              Yes
  Caprini, 2002       Enoxaparin 30 mg twice daily for 7 days versus UFH 5,000 units 3 times daily and warfarin for 10 days                                                                                                                                                       THR                                                               Yes; outcomes taken from RCTs                        Yes; data from literature                                                Yes                                                                              Yes
  Levin, 2001         Desirudin 15 mg twice daily versus enoxaparin 40 mg daily for 10 days                                                                                                                                                                                       THR                                                               Yes; outcomes taken from RCTs                        Yes; data from literature                                                Yes                                                                              Yes
  Honorato, 2004      Bemiparin 3,500 units daily versus enoxaparin 40 mg daily for 8-12 days                                                                                                                                                                                     TKR                                                               Yes; outcomes taken from RCTs                        Yes; data from National Health Care Institute, pharmacists association   Yes                                                                              Yes
  Attanasio, 2001     Dermatan sulfate 300 mg daily versus UFH 5,000 units 3 times daily for 7 days                                                                                                                                                                               Surgical oncology                                                 Yes; outcomes taken from RCTs                        Yes - data from hospital costs                                           Yes                                                                              Yes
  Wade, 2001          Tinzaparin 3,500 units versus enoxaparin 30 mg twice daily for 8 weeks                                                                                                                                                                                      Spinal cord injury                                                Yes; outcomes taken from RCTs                        Yes; data from different hospitals, DRG                                  Yes                                                                              Yes
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   **Were estimates and costs related to the baseline risk in treatment population- are these results generalizable?**
  Gordois, 2003       Enoxaparin 40 mg daily versus fondaparinux 2.5 mg daily for 5-9 days                                                                                                                                                                                        THR, HFS                                                          Yes; outcomes taken from RCTs                        Yes; data from NICE                                                      Yes                                                                              Yes
  Lundkvist, 2003     Fondaparinux 2.5 mg daily versus enoxaparin 40 mg daily for 7 days                                                                                                                                                                                          THR, HFS                                                          Yes; outcomes taken from RCTs                        Yes; data from literature                                                Yes                                                                              Yes
  Wade, 2003          Fondaparinux 2.5 mg daily versus enoxaparin 40 mg daily versus 30 mg twice daily for 7-10 days                                                                                                                                                              HFS                                                               Yes; outcomes taken from RCTs                        Yes; data from literature                                                Yes                                                                              Yes
  Szucs, 2003         Fondaparinux 2.5 mg daily versus enoxaparin 40 mg daily for 7 days                                                                                                                                                                                          THR, TKR HFS                                                      Yes; outcomes taken from RCTs                        Yes; data from literature and surveys in Switzerland                     Yes                                                                              Yes
  Sullivan, 2004      Fondaparinux 2.5 mg daily versus enoxaparin 40 mg daily for 7 days                                                                                                                                                                                          THR, TKR HFS                                                      Yes; outcomes taken from RCTs                        Yes; costs from review of 220 acute care hospitals                       Yes                                                                              Yes
  Dranitsaris, 2004   Fondaparinux 2.5 mg daily versus enoxaparin 40 mg daily for 7 days                                                                                                                                                                                          THR, HFS                                                          Yes; outcomes taken from a meta-analysis             Data from CIHI, surveys                                                  Yes                                                                              Yes
  Spruill, 2004       Fondaparinux 2.5 mg daily versus enoxaparin 30 mg twice daily for 4-5 days                                                                                                                                                                                  TKA                                                               Yes; outcomes taken from RCTs                        Yes; data from literature                                                Yes                                                                              Yes
  Spruill, 2004       Fondaparinux 2.5 mg daily versus enoxaparin 30 mg twice daily for 10 days                                                                                                                                                                                   THR                                                               Yes; outcomes taken from RCTs                        Yes; data from literature                                                Yes                                                                              Yes
  Wade, 2004          Fondaparinux 2.5 mg daily versus enoxaparin 40 mg daily for 7 days                                                                                                                                                                                          HFS                                                               Yes; outcomes taken from RCTs                        Yes; data from literature                                                Yes                                                                              Yes
  Bjorvatn, 2005      Fondaparinux 2.5 mg daily versus enoxaparin 40 mg daily for 7 days                                                                                                                                                                                          THR, TKR HFS                                                      Yes; outcomes taken from RCTs                        Yes; data from Norwegian national sources                                Yes                                                                              Yes
  Wolowacz 2009       THR Dabigatran 220 mg daily versus enoxaparin 40 mg daily for 28-35 days TKR Dabigatran 220 mg daily for versus enoxaparin 40 mg daily 6-10 days                                                                                                            THR, TKR                                                          Yes; outcomes taken from RCTs                        Yes; data from UK national sources                                       Yes                                                                              Yes
  McCullagh, 2009     THR Dabigatran 220 mg daily for 35 days versus rivaroxaban 10 mg daily for 35 days versus enoxaparin 40 mg daily for 14 days TKR Dabigatran 220 mg daily for 14 days versus rivaroxaban 10 mg daily for 10 days versus enoxaparin 40 mg daily for 10 days   THR, TKR                                                          Yes; outcomes taken from RCTs                        Yes; data from literature and Irish national sources                     Yes                                                                              Yes
  Pechevis, 2000      Yes                                                                                                                                                                                                                                                         N/R                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  Lloyd, 2001         Yes                                                                                                                                                                                                                                                         N/R                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  Lamy, 2002          Yes                                                                                                                                                                                                                                                         N/R                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  Offord, 2003        Yes                                                                                                                                                                                                                                                         N/R                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  Schadlich, 2006     Incompletely                                                                                                                                                                                                                                                N/R                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  Drummond, 1994      Incompletely                                                                                                                                                                                                                                                N/R                                                               No                                                   Yes                                                                      Yes                                                                              Likely
  Hawkins, 1997       Yes                                                                                                                                                                                                                                                         N/R                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  Marchetti, 1999     Incompletely                                                                                                                                                                                                                                                N/R                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  Etchells, 1999      Yes                                                                                                                                                                                                                                                         N/R                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  McGarry, 2004       Incompletely                                                                                                                                                                                                                                                N/R                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  **Article**         **Were incremental costs and outcomes measured?**                                                                                                                                                                                                           **Do incremental costs and outcomes differ between subgroups?**   **Does allowance for uncertainty change results?**   **Are prophylaxis benefits worth the harm and costs?**                   **Generalizability: could other patient populations expect similar outcomes?**   **Generalizability: could other patient populations expect to experience similar costs?**
  Heerey, 2005        Incompletely                                                                                                                                                                                                                                                N/R                                                               No                                                   Yes                                                                      Yes                                                                              Likely
  Deitelzweig, 2008   Yes                                                                                                                                                                                                                                                         N/R                                                               No                                                   Yes                                                                      Yes                                                                              Likely
  Wade, 2008          Yes                                                                                                                                                                                                                                                         Yes                                                               Yes                                                  Yes                                                                      Yes                                                                              Yes
  O\'Brien, 1994      Yes                                                                                                                                                                                                                                                         N/R                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  Menzin, 1995        Yes                                                                                                                                                                                                                                                         N/R                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  Hull, 1997          Yes                                                                                                                                                                                                                                                         N/R                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  Hawkins, 1998       Yes                                                                                                                                                                                                                                                         N/R                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  Francis, 1999       Yes                                                                                                                                                                                                                                                         Yes                                                               Yes                                                  Likely                                                                   Yes                                                                              Yes
  Botteman, 2002      Incompletely                                                                                                                                                                                                                                                N/R                                                               No                                                   Yes                                                                      Perhaps                                                                          Yes
  Nerurkar, 2002      Incompletely                                                                                                                                                                                                                                                N/R                                                               No                                                   Yes                                                                      Perhaps                                                                          Yes
  Levin, 2001         Incompletely                                                                                                                                                                                                                                                N/R                                                               No                                                   Yes                                                                      Yes                                                                              Likely
  Caprini, 2002       Yes                                                                                                                                                                                                                                                         Yes                                                               No                                                   Yes                                                                      Yes                                                                              Likely
                      **Were incremental costs and outcomes measured?**                                                                                                                                                                                                           **Do incremental costs and outcomes differ between subgroups?**   **Does allowance for uncertainty change results?**   **Are prophylaxis benefits worth the harm and costs?**                   **Generalizability: could other patient populations expect similar outcomes?**   **Generalizability: could other patient populations expect to experience similar costs?**
  Honorato, 2004      Yes                                                                                                                                                                                                                                                         N/R                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  Wade, 2001          Incompletely                                                                                                                                                                                                                                                N/R                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  Gordois, 2003       Yes                                                                                                                                                                                                                                                         N/R                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  Wade, 2003          Yes                                                                                                                                                                                                                                                         N/R                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  Annemans, 2004      Yes                                                                                                                                                                                                                                                         N/R                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  Attanasio, 2001     Yes                                                                                                                                                                                                                                                         N/R                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  Szucs, 2003         Yes                                                                                                                                                                                                                                                         Yes                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  Sullivan, 2004      Yes                                                                                                                                                                                                                                                         Yes                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  Dranitsaris, 2004   Yes                                                                                                                                                                                                                                                         N/R                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  Spruill, 2004       Yes                                                                                                                                                                                                                                                         N/R                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  Spruill, 2004       Yes                                                                                                                                                                                                                                                         N/R                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  Wade, 2004          Yes                                                                                                                                                                                                                                                         N/R                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  Bjorvatn, 2005      Yes                                                                                                                                                                                                                                                         Yes                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  Wolowacz 2009       Yes                                                                                                                                                                                                                                                         Yes                                                               No                                                   Yes                                                                      Yes                                                                              Yes
  McCullagh 2009      Yes                                                                                                                                                                                                                                                         Yes                                                               No                                                   Yes                                                                      Yes                                                                              Yes

CIHI, Canadian Institute for Health Information; DRG, diagnosis-related group; HFS, hip fracture surgery; NICE, National Centre for Clinical Excellence

N/R, not reported; OHIP, Ontario Health Insurance Plan; RCT, randomized controlled trial; THR, total hip replacement; TKR, total knee replacement; UFH, unfractionated heparin.

Twenty-six evaluations were performed in orthopedic patients \[[@B25]-[@B27],[@B34]-[@B43],[@B46]-[@B58]\]; five in other surgical populations \[[@B28],[@B30]-[@B32],[@B44]\], and eight in medical patients \[[@B20]-[@B24],[@B29],[@B33],[@B45]\]. All 39 studies were either decision analytic models based on individual randomized controlled trials \[[@B20]-[@B22],[@B24],[@B26],[@B28],[@B31]-[@B49],[@B51]-[@B58]\] or meta-analysis \[[@B23],[@B27],[@B29],[@B30],[@B51]\].

Study perspectives, time horizon, and funding
---------------------------------------------

The studies were conducted from a North American or European economic perspective: 18 of the studies were conducted in the United States \[[@B26],[@B29],[@B31]-[@B41],[@B45],[@B48],[@B51]-[@B53],[@B55]\], six in the United Kingdom \[[@B21],[@B23],[@B25],[@B46],[@B57],[@B58]\], four in Canada \[[@B23],[@B28],[@B34],[@B51]\], and three in Italy \[[@B27],[@B30],[@B44]\], two in Sweden \[[@B42],[@B47]\], and one each in Spain \[[@B43]\], Belgium \[[@B49]\], France \[[@B20]\], Norway \[[@B54]\], Switzerland \[[@B56]\], and Germany \[[@B24]\]. Seven studies were conducted from the perspective of the hospital \[[@B24],[@B41],[@B42],[@B44],[@B45],[@B49],[@B53]\], four from a societal perspective \[[@B20],[@B28],[@B30],[@B32]\], nine from the perspective of another specific payer \[[@B23],[@B31],[@B33],[@B40],[@B54]-[@B58]\], and the remaining 19 studies did not clearly specify which perspective was used.

The prophylaxis time horizons considered were variable: either for 5 days \[[@B33],[@B51]\]; 7 days \[[@B25],[@B28],[@B34],[@B38],[@B44],[@B46]-[@B50],[@B53]-[@B56]\]; 6 to 14 days \[[@B23]\]; 10 days \[[@B31],[@B32],[@B37],[@B40],[@B41],[@B52]\], 8 to 12 days \[[@B43]\]; 7 to 14 days \[[@B26]\]; 6 to 14 days \[[@B57]\], 10 to 14 days \[[@B20],[@B22]-[@B24],[@B27],[@B30],[@B35],[@B36],[@B39],[@B42]-[@B46]\]; 30 days \[[@B29]\], 8 to 33 days \[[@B59]\], and another for 8 weeks \[[@B45]\]. Twenty-five studies received some sponsorship by pharmaceutical companies \[[@B20],[@B22]-[@B25],[@B28],[@B30],[@B33]-[@B38],[@B40],[@B41],[@B43],[@B44],[@B46],[@B47],[@B50],[@B54]-[@B56],[@B58]\].

Study quality
-------------

All 39 studies that were of *high*quality were included in this systematic review (Table [2](#T2){ref-type="table"}). Eighteen of these showed complete cost data but did not present complete effectiveness data \[[@B25]-[@B27],[@B29],[@B31],[@B37]-[@B45],[@B51],[@B54]-[@B56]\]. The remaining 17 studies had complete cost and effectiveness data. Six of the studies obtained effectiveness data from meta-analysis \[[@B23],[@B25],[@B27],[@B31],[@B50],[@B57]\], whereas the remainder obtained effectiveness data from one or more randomized controlled trials. Six of these studies obtained effectiveness data from a single trial \[[@B20],[@B22]-[@B24],[@B33],[@B41]\]. All studies, with the exception of one \[[@B23]\], obtained cost data from multiple sources, including actual and estimated healthcare system costs, randomized controlled trials, literature reviews, and other national government sources. All performed sensitivity analyses of some description.

Cost and effect estimates
-------------------------

### Low Molecular Weight Heparins versus Placebo

Among the five studies comparing low-molecular-weight heparins with placebo in medical patients, enoxaparin was the most economically attractive strategy in all five studies and dominant in two \[[@B20],[@B22]\], with incremental cost-efficacy ratios ranging from \$83 to \$1,711 per venous thromboembolism event avoided in three others \[[@B21],[@B23],[@B24]\]; cost per life-year or quality-adjusted life-year gained were not investigated (Table [3](#T3){ref-type="table"}). Sensitivity analysis did not alter these findings. Four of the five studies were sponsored by the manufacturer of enoxaparin \[[@B20]-[@B22],[@B24]\].

###### 

Incremental costs, effects, and cost-efficacy ratios for the different modes of venous thromboembolism prophylaxis

  Low-molecular-weight heparins versus placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  ------------------------------------------------------------------------ ----------------------------- -------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------
  \*Pechevis, 2000                                                         Medical                       Net saving (value not reported) per 1,000 patients with enoxaparin         94 DVT/PE avoided, four lives (estimated 12 life-years) gained, per 1,000 patients with enoxaparin          Enoxaparin dominant                                                                                    Not reported                                                                                                                                                                                              Enoxaparin
  Lloyd, 2001                                                              Medical                       \$20,680 per 1,000 patients with enoxaparin                                20 VTE events avoided per 1,000 patients with enoxaparin                                                    \$1, 034 per VTE avoided with enoxaparin                                                               Six more major bleeding events per 1,000 patients with enoxaparin                                                                                                                                         Enoxaparin
  \*Lamy, 2002                                                             Medical                       \$1, 910 per 1,000 patients in tertiary care setting with enoxaparin       2.3% fewer VTE events with enoxaparin                                                                       \$83 per VTE avoided with enoxaparin                                                                   Not reported                                                                                                                                                                                              Enoxaparin
  \*Offord, 2004                                                           Medical                       Net saving (\$26,478) per 1,000 patients with enoxaparin                   14 VTE events and 3.5 deaths avoided per 1,000 patients with enoxaparin                                     Enoxaparin dominant                                                                                    Not reported                                                                                                                                                                                              Enoxaparin
  \*Schaldich, 2006                                                        Medical                       \$44,665 per 1,000 patients with enoxaparin                                26 VTE events avoided per 1,000 patients with enoxaparin                                                    \$1, 711 per VTE avoided with enoxaparin                                                               Not reported                                                                                                                                                                                              Enoxaparin
  **Low-molecular-weight heparins versus unfractionated heparin**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  **Reference**                                                            **Patient population**        **Incremental cost (USD)**                                                 **Incremental effects (VTE avoided or life-years or QALYS gained)**                                         **ICER (USD/VTE event avoided or life-years or QALYS gained)**                                         **Bleeding complications**                                                                                                                                                                                **Most economically attractive drug**
  \*Drummond, 1994, enoxaparin                                             HFS                           Net saving (\$43,609) per 1,000 patients with enoxaparin                   Four deaths avoided per 1,000 patients with enoxaparin                                                      Enoxaparin dominant                                                                                    Not reported                                                                                                                                                                                              Enoxaparin
  \*Hawkins, 1997, enoxaparin                                              THR                           \$57,972 per 1,000 patients with enoxaparin                                47 DVT events avoided per 1,000 patients with enoxaparin                                                    \$1, 180 per VTE event avoided with enoxaparin                                                         Not reported (implied enoxaparin increased bleeding risk)                                                                                                                                                 Enoxaparin
  Marchetti, 1999, enoxaparin                                              THR                           Net saving (\$90,000) per 1,000 patients with enoxaparin                   70 life-years gained per, 1000 patients with enoxaparin                                                     Enoxaparin dominant                                                                                    Not reported                                                                                                                                                                                              Enoxaparin
  \*Etchells, 1999, enoxaparin                                             Colorectal surgery            \$180,641 per 1,000 patients with enoxaparin                               0 VTE events avoided with enoxaparin                                                                        UFH dominant                                                                                           12 additional major bleeding events with enoxaparin                                                                                                                                                       UFH
  Lloyd, 2001, enoxaparin                                                  Medical                       Net saving (\$850) per 1,000 patients with enoxaparin                      21 VTE events avoided per 1,000 patients with enoxaparin                                                    Enoxaparin dominant                                                                                    18 fewer major bleeding events with Enoxaparin                                                                                                                                                            Enoxaparin
  \*Offord, 2003, enoxaparin                                               Medical                       Net saving (\$54,649) per 1,000 patients with Enoxaparin                   20.5 VTE events and 0.5 deaths avoided per 1,000 patients with enoxaparin                                   Enoxaparin dominant                                                                                    Not reported                                                                                                                                                                                              Enoxaparin
  \*McGarry, 2004, enoxaparin                                              Medical                       \$14,459 per 1,000 patients with enoxaparin                                10 VTE events and 4.4 deaths avoided per 1,000 patients with enoxaparin                                     \$1, 445 per VTE event avoided, and \$10,360 per death avoided with enoxaparin                         2.7% fewer bleeding events, 0.9% fewer episodes of HIT                                                                                                                                                    Enoxaparin
  \*Schadlich, 2006, enoxaparin                                            Medical                       Net saving (\$46,499) per 1,000 patients with Enoxaparin                   N/R                                                                                                         Enoxaparin dominant                                                                                    7.7 fewer major bleeding episodes with enoxaparin                                                                                                                                                         Enoxaparin
  \*Deitelzweig, 2008                                                      Medical                       Net saving (\$339,361) per 1,000 patients with enoxaparin                  11 VTE events, three deaths avoided per 1,000 patients with enoxaparin                                      Enoxaparin dominant                                                                                    Five major bleeding events, four episodes of HIT avoided per 1,000 patients with enoxaparin                                                                                                               Enoxaparin
  Wade, 2008, enoxaparin                                                   Gynecology oncology Surgery   Net saving (\$36,197) per 1,000 patients with enoxaparin                   Eight DVTs, 18 PE events avoided per 1,000 patients with enoxaparin                                         Enoxaparin dominant                                                                                    21 additional major bleeding events per 1,000 patients with enoxaparin                                                                                                                                    Enoxaparin
  \*Lloyd, 1997, nadroparin                                                Orthopedics                   Net savings (\$192,000) per 1,000 patients with enoxaparin                 50 VTE events avoided per 1,000 patients with enoxaparin                                                    Enoxaparin dominant                                                                                    Not reported                                                                                                                                                                                              Nadroparin
                                                                           General surgery               Net savings (\$33,000) per 1,000 patients with enoxaparin                  Nine VTE events avoided per 1,000 patients with enoxaparin                                                  Nadroparin dominant                                                                                    Not reported                                                                                                                                                                                              Nadroparin
  Heerey, 2005, dalteparin                                                 General surgery               \$473,000 per 1,000 patients with dalteparin                               21 QALYs per 1,000 patients with dalteparin                                                                 \$20,337/QALY gained with dalteparin                                                                   Not reported                                                                                                                                                                                              Dalteparin
  **Low-molecular-weight heparins versus warfarin**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  **Reference**                                                            **Patient population**        **Incremental cost (USD)**                                                 **Incremental effects (VTE avoided or life-years or QALYS gained)**                                         **ICER (USD/VTE event avoided or life-years or QALYS gained)**                                         **Bleeding complications**                                                                                                                                                                                **Most economically attractive drug**
  \*O\'Brien, 1994, enoxaparin                                             THR                           \$133,571 per 1,000 patients with LMWH                                     Five VTE events, 0.4 deaths avoided per 1,000 patients with LMWH                                            \$26,711 per VTE event avoided, \$334,055 per death avoided, \$32,158 per life-year gained with LMWH   Not reported                                                                                                                                                                                              LMWH
  \*Menzin, 1995, enoxaparin                                               THR                           \$69,659 per 1,000 patients with LMWH                                      20.1 VTE events and 4.3 deaths avoided per 1,000 patients with LMWH                                         \$3,466 per VTE avoided, \$16,200 per additional death avoided                                         Not reported                                                                                                                                                                                              LMWH
  \*Hull, 1997, tinzaparin                                                 TKR, THR                      Net saving (\$52,690) per 1,000 patients with LMWH                         60 VTE events avoided per 1,000 patients with LMWH                                                          LMWH dominant                                                                                          2.2% increase in major bleeding events with LMWH                                                                                                                                                          LMWH
  \*Hawkins, 1998, enoxaparin                                              TKR                           \$126,766 per 1,000 patients with LMWH                                     145 VTE events avoided per 1,000 patients with LMWH                                                         \$874 per VTE event avoided with LMWH                                                                  0.3% increased risk of major bleeding event with LMWH                                                                                                                                                     LMWH
  \*Francis, 1999                                                          THR                           Net saving (\$153,000) per 1,000 patients treated with LMWH                112 VTE events avoided per 1,000 patients with LMWH                                                         LMWH dominant                                                                                          62 more patients with bleeding event with LMWH                                                                                                                                                            LMWH
  \*Botteman, 2002, enoxaparin                                             THR                           \$154,000 per 1,000 patients with LMWH                                     77 DVTs avoided per 1,000 patients, 40 QALYs gained per 1,000 patients with LMWH                            \$2013 per DVT avoided, \$40,169 per death avoided, \$4349 per QALY gained with LMWH                   Not reported                                                                                                                                                                                              LMWH
  Nerurkar, 2002, enoxaparin                                               TKR                           Net saving (\$1, 054,000) per 1,000 patients with LMWH                     Seven deaths avoided per 1,000 patients with LMWH                                                           LMWH dominant                                                                                          Not reported                                                                                                                                                                                              LMWH
  \*Caprini, 2002                                                          THR                           \$110,235 per 1,000 patients with LMWH                                     5.8 VTE events avoided per 1,000 patients with LMWH                                                         \$19,006 per VTE event avoided with LMWH                                                               Not reported                                                                                                                                                                                              LMWH
  **Comparison of low-molecular-weight heparins and other agents**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  **Reference**                                                            **Patient population**        **Incremental cost (USD)**                                                 **Incremental effects (VTE avoided or life-years or QALYS gained)**                                         **ICER (USD/VTE event avoided or life-years or QALYS gained)**                                         **Bleeding complications**                                                                                                                                                                                **Most economically attractive drug**
  Levin, 2001, desirudin versus enoxaparin                                 THR                           \$72,000 per 1,000 patients                                                19.1 life-years gained per 1,000 patients with desirudin                                                    \$3,794 per life-year gained                                                                           Not reported                                                                                                                                                                                              Desirudin
  \*Honorato, 2004, bemiparin versus enoxaparin                            TKR                           Net savings (\$227,000) per 1,000 patients with bemiparin                  42 VTE events avoided per 1,000 patients with bemiparin                                                     Bemiparin dominant                                                                                     Not reported                                                                                                                                                                                              Bemiparin
  \*Attanasio, 2001, dermatan sulfate versus UFH 5,000 U, 3 times daily    Surgical cancer               Net saving (\$53,000) per 1,000 patients with dermatan sulfate             70 DVTs avoided and 3.1 lives gained per 1,000 patients with dermatan sulfate                               Dermatan sulfate dominant                                                                              Five additional major bleeding events with dermatan sulfate                                                                                                                                               Dermatan sulfate
  Heerey, 2005, dalteparin 2,500 U versus dalteparin, 5,000 U              Abdominal surgery             \$477,000 per 1,000 patients with dalteparin                               18 QALYs per 1,000 patients with dalteparin                                                                 \$24,357/QALY gained with dalteparin                                                                   Not reported                                                                                                                                                                                              Dalteparin 5,000 U
  Wade, 2001, tinzaparin versus enoxaparin                                 Spinal cord injury            \$223,259 per 1,000 patients with enoxaparin                               Not reported                                                                                                Not reported                                                                                           Not reported                                                                                                                                                                                              Not reported
  **Fondaparinux versus enoxaparin**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  **Reference**                                                            **Patient population**        **Incremental cost (USD)**                                                 **Incremental effects (VTE avoided or life-years or QALYS gained)**                                         **ICER (USD/VTE event avoided or life-years or QALYS gained)**                                         **Bleeding complications**                                                                                                                                                                                **Most economically attractive drug**
  \*Gordois, 2003                                                          THR, TKR, HFS                 \$10,000 per 1,000 patients by discharge from hospital with fondaparinux   11 VTE events, 1.9 deaths avoided per 1,000 patients by discharge from hospital with fondaparinux           \$1, 077 per VTE event avoided and \$5,317 per death avoided with fondaparinux                         Not reported                                                                                                                                                                                              Fondaparinux
  \*Lundkvist, 2003                                                        THR, TKR, HFS                 Net saving (\$59,000) per 1,000 patients with fondaparinux                 17.9 VTE events, 2.6 deaths avoided per 1,000 patients (average among three conditions) with fondaparinux   Fondaparinux dominant                                                                                  Not reported                                                                                                                                                                                              Fondaparinux
  Wade, 2003, enoxaparin, 30 mg twice daily enoxaparin, 40 mg once daily   THR                           Net savings (\$168,382) per 1,000 patients with enoxaparin                 Three VTE events per 1,000 patients with enoxaparin                                                         Enoxaparin dominant                                                                                    27 more bleeding episodes per 1,000 patients with fondaparinux compared with twice-daily enoxaparin Six more bleeding episodes per 1,000 patients with enoxaparin once daily compared with fondaparinux   Enoxaparin twice daily
  Annemans, 2004                                                           THR, TKR, HFS                 \$2,800 per 1,000 patients with fondaparinux                               17.7 VTE events per 1,000 patients with fondaparinux                                                        \$158 per VTE event avoided; \$104 per death avoided with fondaparinux                                 1.6 more bleeding episodes per 1,000 patients with fondaparinux                                                                                                                                           Fondaparinux
  \*Dranitsaris, 2004                                                      THR, TKR, HFS                 Net saving (\$50,000) per 1,000 patients with fondaparinux                 16 VTE avoided per 1,000 patients with fondaparinux                                                         Fondaparinux dominant                                                                                  10 more major bleeding events per 1,000 patients with fondaparinux                                                                                                                                        Fondaparinux
  Spruill, 2004                                                            TKR (2002 USD)                Net saving (\$43,549) per 1,000 patients with fondaparinux                 36 VTE events avoided per 1,000 patients with fondaparinux                                                  Fondaparinux dominant                                                                                  10 more major bleeds and three more minor bleeding events per 1,000 patients with fondaparinux                                                                                                            Fondaparinux
  Spruill, 2004                                                            THR (2002 USD)                Net saving (\$18,898) per 1,000 patients with fondaparinux                 20 VTE events avoided per 1,000 patients with fondaparinux                                                  Fondaparinux Dominant                                                                                  19 more major bleeding events per 1,000 patients with fondaparinux                                                                                                                                        Fondaparinux
  Wade, 2004                                                               HFS                           \$21,171 per 1,000 patients with fondaparinux                              34 VTE events avoided per 1,000 patients with fondaparinux                                                  \$623 per VTE avoided, \$32,144 per QALY gained with fondaparinux                                      Approximately 20% increased bleeding costs for fondaparinux                                                                                                                                               Fondaparinux
  \*Sullivan, 2004                                                         THR, TKR, HFS                 Net savings (\$67,000) per 1,000 patients treated with fondaparinux        3.7 VTE events avoided per 1,000 patients with Fondaparinux                                                 Fondaparinux dominant                                                                                  Two more bleeding events per 1000 patients with Fondaparinux                                                                                                                                              Fondaparinux
  \*Szucs, 2005                                                            THR, TKR, HFS                 Net savings (\$18,153) per 1,000 patients treated with fondaparinux        8.1 VTE events avoided per 1,000 patients with fondaparinux                                                 Fondaparinux dominant                                                                                  1.6 more bleeding events per 1,000 patients with fondaparinux                                                                                                                                             Fondaparinux
  \*Bjorvatn, 2005                                                         THR, TKR, HFS                 \$53,553 per 1,000 patients treated with fondaparinux                      7.2 VTE events avoided per 1,000 patients with fondaparinux                                                 \$753 per VTE avoided, \$6,782 per death avoided with fondaparinux                                     Two more bleeding events per 1,000 patients treated with fondaparinux                                                                                                                                     Fondaparinux
  **Dabigatran versus rivaroxaban and low-molecular-weight heparins**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Wolowacz, 2009                                                           THR                           THR Net savings (\$103,050) per 1,000 patients treated with dabigatran     Two VTEs avoided, eight life-years, six QALYs gained per 1,000 patients treated with dabigatran             Dabigatran dominant                                                                                    Five additional major bleeding events, two episodes HIT avoided per 1,000 patients treated with dabigatran                                                                                                Dabigatran
                                                                           TKR                           Net savings (\$8,162) per 1,000 patients treated with dabigatran           Four VTEs avoided, 9 life-years, 7 QALYs gained per 1,000 patients treated with dabigatran                  Dabigatran dominant                                                                                    Six additional major bleeding events, two episodes HIT avoided per 1,000 patients treated with dabigatran                                                                                                 
  McCullagh, 2009                                                          THR                           Net savings (\$24,104) per 1,000 patients treated with rivaroxaban         7 Life-years, 10 QALYs gained per 1,000 patients with rivaroxaban                                           Rivaroxaban dominant                                                                                   Not reported                                                                                                                                                                                              Rivaroxaban
                                                                           TKR                           Net savings (\$213,452) per 1,000 patients treated with rivaroxaban        7 Life-years, 12 QALYs gained per 1,000 patients with rivaroxaban                                           Rivaroxaban dominant                                                                                                                                                                                                                                                                                             

HFS, hip-fracture surgery; ICER, incremental cost-efficacy ratio; LMWH, low-molecular-weight heparin; THR, total hip replacement; UFH, unfractionated heparin; USD, United States dollars; VTE, venous thromboembolism. \*Industry-sponsored study.

### Unfractionated Heparin versus Low Molecular Weight Heparins

Among the 12 studies comparing low-molecular-weight heparins with unfractionated heparin among medical and surgical patients, 11 found that low-molecular-weight heparins were more effective (Table [3](#T3){ref-type="table"} and Figure [2](#F2){ref-type="fig"}). Eight of the 12 studies comparing low-molecular-weight heparins with unfractionated heparin found low-molecular-weight heparins to be the dominant strategy \[[@B21],[@B23]-[@B25],[@B27],[@B29],[@B30],[@B32],[@B33]\]. Two studies reported an incremental cost-efficacy ratio of \$1,180 and \$1,445 per venous thromboembolism event avoided when using enoxaparin \[[@B26],[@B29]\], and two studies found incremental cost-effectiveness ratios of \$10,360 per death avoided and \$20,337 per quality-adjusted life-year gained with low-molecular-weight heparins. A single study of venous thromboembolism prevention among patients undergoing colorectal cancer surgery found no difference in efficacy, yet costs of low-molecular-weight heparins were greater \[[@B28]\]. Three studies reported increased bleeding risk with low-molecular-weight heparins, and three studies reported lower risk. Sensitivity analyses did not change these results. Of these 12 studies, eight received financial support from the manufacturer of the low-molecular-weight heparins \[[@B23]-[@B26],[@B28]-[@B30],[@B33]\].

![**Comparison of the incremental effects and costs of low-molecular-weight heparin versus unfractionated heparin for venous thromboembolism prophylaxis**.](cc11241-2){#F2}

### Warfarin versus Low-Molecular-Weight Heparins

Low-molecular-weight heparins were reported to be economically more attractive than warfarin in all eight studies among surgical patients, with incremental cost-efficacy ratios of \$874 to \$26,711 per venous thromboembolism event avoided in five of the comparisons \[[@B34],[@B35],[@B37],[@B38],[@B40]\], the dominant strategy in three comparisons \[[@B36],[@B39],[@B41]\]. Long-term outcomes varied widely, with \$16,200 to \$334,055 per death avoided, \$32,158 per life-year and \$4,340 per quality-adjusted life-year gained (Table [3](#T3){ref-type="table"} and Figure [3](#F3){ref-type="fig"}) \[[@B34],[@B38]\]. Sensitivity analyses did not change the results in individual studies. Of these eight studies, seven received pharmaceutical sponsorship \[[@B34]-[@B38],[@B40],[@B41]\].

![**Comparison of the incremental effects and costs of low-molecular-weight heparin versus warfarin for venous thromboembolism prophylaxis**.](cc11241-3){#F3}

### Low-Molecular-Weight Heparins versus One another, and Other Comparisons

Within the studies comparing low-molecular-weight heparins with one another and with other anticoagulants among surgical patients, bemiparin and dermatan sulfate were the dominant prophylaxis over enoxaparin \[[@B43],[@B44]\]. Desirudin had an incremental cost-effectiveness ratio of \$3,794 per life-year gained, whereas enoxaparin was favored over tinzaparin but was more expensive (Table [3](#T3){ref-type="table"}) \[[@B45]\]. Dalteparin, 5,000 units once daily, was more efficacious than dalteparin, 2,500 units, with an incremental cost-effectiveness ratio of \$24,357 per quality-adjusted life-year gained \[[@B30]\].

### Fondaparinux versus Low Molecular Weight Heparins

Among the 11 studies comparing fondaparinux with enoxaparin, all were conducted in orthopedic surgery patients, and all concluded that fondaparinux was economically attractive. In six, fondaparinux was dominant \[[@B47],[@B51]-[@B53],[@B55],[@B56]\], and in one, enoxaparin \[[@B48]\] (Table [3](#T3){ref-type="table"} and Figure [4](#F4){ref-type="fig"}). In four studies, incremental cost-effectiveness ratios of fondaparinux over enoxaparin were \$158 to \$1,077 per venous thromboembolism event avoided, \$104 to \$6,782 per death avoided, and \$32,144 per quality-adjusted life-year gained \[[@B46],[@B49],[@B53],[@B54]\]. In eight of 11 studies, fondaparinux was associated with increased bleeding risk. Sensitivity analyses of the various costs did not alter the findings. The manufacturer of fondaparinux provided sponsorship for six of the 11 studies.

![**Comparison of the incremental effects and costs of low-molecular-weight heparin versus fondaparinux for venous thromboembolism prophylaxis**.](cc11241-4){#F4}

### Dabigatran and Rivaroxaban versus Low Molecular Weight Heparins

Among orthopedic patients, dabigatran, in comparison with enoxaparin, was dominant, with cost savings of \$103,050 and \$8,162 and six and seven quality-adjusted life-years gained per 1,000 patients with a total hip replacement and total knee replacement, respectively \[[@B58]\]. Comparing rivaroxaban, dabigatran, and enoxaparin among orthopedic surgery patients, rivaroxaban was dominant, with cost savings of \$24,104 and \$213,452 and 7 life-years gained per 1,000 patients with a total hip replacement and total knee replacement, respectively \[[@B57]\].

### Sponsorship and Economic Comparisons

When comparing different populations and the different modes of venous thromboembolism prophylaxis, we observed several interesting trends. All studies comparing fondaparinux, rivaroxaban, or dabigatran with enoxaparin were performed in orthopedic patients, and the remainder of the studies in this patient population examined various low-molecular-weight heparins or warfarin. Sixteen of the 25 studies among orthopedic patients were sponsored in some manner by the pharmaceutical industry: six studies favored fondaparinux \[[@B46],[@B47],[@B50],[@B54]-[@B56]\]; one, rivaroxaban \[[@B57]\]; one, dabigatran \[[@B58]\]; and the remainder favored low-molecular-weight heparins \[[@B25],[@B34]-[@B38],[@B40],[@B41],[@B43]\]. In comparison, five of the eight studies conducted in medical patients compared enoxaparin with placebo \[[@B20]-[@B24]\]; two compared unfractionated heparin with enoxaparin \[[@B29],[@B33]\]; and the final one compared enoxaparin with tinzaparin \[[@B45]\]. Five of these eight studies were sponsored by pharmaceutical companies, and all studies favored enoxaparin \[[@B20],[@B22]-[@B24]\]. Of the five studies in other surgical populations, three were sponsored by the pharmaceutical industry, and these studies favored unfractionated heparin \[[@B28]\], nadroparin \[[@B30]\], and dermatan sulfate \[[@B44]\].

Of the economic evaluations included in this review, 25 (64%) received funding by manufacturers of one of the comparators. The \"new\" agent within the comparison was deemed to have a favorable (dominant or attractive incremental cost-effectiveness ratio) outcome in 38 (97.4%) of the 39 economic evaluations (95% CI, 86.5% to 99.9%). Among the 25 studies funded by a pharmaceutical company, the sponsored medication was reported to be economically attractive in 24 (96.0%) (95% CI, 80.0% to 99.9%).

Discussion
==========

In this systematic review of economic analyses of venous thromboembolism-prevention strategies in hospitalized patients, we found that all of the high-quality studies focused on pharmacologic prophylaxis. Low-molecular-weight heparins were the most commonly studied \"new\" class of medication and were generally reported to be the dominant or economically attractive strategy in comparison with placebo, unfractionated heparin, or warfarin, among medical and surgical patients. However, among orthopedic patients, fondaparinux was favored over low-molecular-weight heparins. The two newest agents, dabigatran and rivaroxaban, are favored in the two most recent orthopedic surgery evaluations included in this review. Among the various strategies compared, the new agent had a favorable cost-efficacy ratio in 97% of the studies, and most of these studies were sponsored by the manufacturers of the new agent.

Few systematic reviews of economic analyses comparing different modes of venous-thromboembolism prophylaxis in hospitalized patients have been conducted. In 1994, one such review of cost-efficacy analyses of low-molecular-weight heparins, unfractionated heparin, and warfarin in the prevention and treatment of venous thromboembolism in surgical patients, concluded that low-molecular-weight heparin was more efficacious and cost-effective after total hip arthroplasty \[[@B34]\]. Most recently, a trial comparing low-molecular-weight heparin with unfractionated heparin in hospitalized patients found low-molecular-weight heparin to be cost saving compared with unfractionated heparin and that low-molecular-weight heparin was associated with a lower venous thromboembolism readmission rate at 30 and 90 days \[[@B59]\]. Our review includes 37 subsequently published analyses, focusing on both medical and surgical patient populations, and comparing newer pharmacologic agents for venous thromboembolism prophylaxis, such as fondaparinux, dabigatran, and rivaroxaban.

In this review, low-molecular-weight heparins appeared to offer superior prophylaxis efficacy compared with warfarin, unfractionated heparin, and placebo for orthopedic, general surgical, and medical patients. Fondaparinux was found to be economically more attractive for venous thromboembolism prevention compared with heparins because of greater efficacy in surgical and orthopedic patients, but may also be associated with increased bleeding. Among 11 economic analyses comparing enoxaparin with fondaparinux, all found that fondaparinux was economically attractive. More than half of these studies were either directly sponsored by the manufacturers of fondaparinux, or were based on original randomized controlled trials funded by the manufacturer.

Historically, many economic evaluations of new drugs have been sponsored by the drug manufacturer. However, this introduces the potential for bias in model construction and interpretation of the results. In a retrospective analysis of 107 trials in five leading medical journals with regard to outcome and sources of funding, studies sponsored by pharmaceutical companies were much less likely to favor traditional therapy over new drug treatment \[[@B60],[@B61]\]. It is not surprising that new agents are incrementally efficacious; this is the nature of progress in medicine. However, new agents, typically still under patent protection, are virtually always substantially more expensive than comparator drugs. In our systematic review, 25 of the 39 studies were funded by pharmaceutical companies, and, with the exception of a single study \[[@B28]\], each of these found the sponsored drug more economically attractive than the comparator drug. Such consistency in incremental cost-effectiveness among more-expensive drugs is striking. Importantly, we could not detect a consistent bias in outcome between sponsored and nonsponsored evaluations; however, only a minority of evaluations did not receive sponsorship.

Strengths of our review include adherence to rigorous systematic review methods, which consisted of a comprehensive search strategy, broad eligibility criteria, and study selection by two independent adjudicators using *a priori*criteria to minimize selection bias. Economic analyses are susceptible to investigator bias, often due to retrospective decision-model generation and retrospective acquisition of cost-and-effect data. To reduce this risk, we included only economic evaluations that incorporated outcome data from prospective randomized controlled trials. We conducted data abstraction and critical appraisal in duplicate, by using established criteria for assessing economic evaluations. We also addressed the relation of recency to market and for-profit sponsorship in influencing the reporting of economic evaluations. This review also has limitations. Many of the analyses within studies that we included come from a limited number of trials and cost-comparison models. For example, five studies used outcome data from the MEDENOX trial \[[@B20],[@B22]-[@B24],[@B33]\]. If most of the data are derived from a limited number of efficacy trials and cost models, similar results are likely to be found across economic evaluations. Although the studies included in this review received high ratings of internal validity, studies varied widely with respect to patient population, time-horizon of therapy, and payer perspective, making generalizability to other health care difficult. In addition, many evaluations rely on radiologic as opposed to clinical venous thromboembolism detection, which may overestimate the real-life clinical consequences of venous thromboembolism. Side effects of thromboprophylaxis may be underestimated, as randomized controlled trials often exclude patients at higher risk of bleeding. Furthermore, trials are generally underpowered to detect differences in rare drug-specific complications such as heparin-induced thrombocytopenia. This may lead to an overestimation of cost-efficacy, as reported in the economic evaluations in this review. Finally, our review included a predominance of orthopedic, general surgery, and medical patients, and thus, our findings may not generalizable to other patient populations.

Among economic analyses in this review, incremental cost-effectiveness ratios were commonly expressed in costs per venous thromboembolism events avoided, and they ranged from \$500 to \$8,000 per venous thromboembolism event avoided. These ranges are difficult to interpret, as no firmly established willingness-to-pay benchmarks exist for venous thromboembolism prevention. Costs per life-year or quality-adjusted life-year gained were less commonly reported, making economic comparisons of venous thromboembolism-prevention strategies and other interventions in healthcare similarly challenging. Comparing and combining ICERs performed with country-specific costs is challenging, as patient, disease, provider, and health-care system factors may influence transferability. We have not adjusted costs based on country-specific purchasing power parity but have adjusted based on changes in gross domestic product over time, and country-specific exchange rates \[[@B62]\].

An informative economic analysis should include both benefits and harms of interventions and the full associated costs over a relevant time horizon. Full costs of venous thromboembolism prophylaxis were not included in some studies. The common complications of venous thromboembolism prophylaxis include prophylaxis failure, leading to thrombotic events, bleeding, and heparin-induced thrombocytopenia \[[@B1]\]. All 39 studies evaluated in this systematic review accounted for breakthrough thrombotic events; however, only half included bleeding complications (Table [3](#T3){ref-type="table"}), and none fully accounted for heparin-induced thrombocytopenia. The omission of these potentially serious complications may considerably affect the cost-comparison data of the individual studies. Most studies ascertained costs retrospectively and from the literature. This is often less complete or less accurate compared with prospective determination alongside a randomized controlled trial. Finally, none of the studies included in this review was prospectively designed before results of the randomized controlled trials were published; accordingly, they may be at risk for subjective decision-tree construction and interpretation.

Few studies have evaluated the cost-effectiveness of mechanical venous thromboembolism-prevention strategies, and none of the existing studies met our eligibility criteria. The UK National Institute for Health and Clinical Excellence have recommended considering graduated compression stockings in most patients, although economic evaluations of mechanical venous thromboembolism prophylaxis have generally been of low quality \[[@B63]\]. The paucity of rigorous evidence about the cost effectiveness of mechanical prophylaxis is striking. However, this may be explained by the fact that manufacturers of mechanical devices are often not required to furnish either effectiveness or cost data to regulatory bodies before their introduction and marketing.

Conclusion
==========

In this systematic review of economic analyses of venous thromboembolism-prevention strategies in hospitalized patients, we found that low-molecular-weight heparins appear to be the most economically attractive strategy for venous thromboembolism prevention among the majority of medical and surgical patients, whereas fondaparinux is more economically attractive for orthopedic patients. The studies, however, may be at risk of overestimating efficacy and underestimating side effects such as bleeding. Approximately two thirds of all evaluations were directly funded by the manufacturer of the new drug, and such drugs were more likely to be found economically attractive in comparison to other strategies. Limited opportunity for peer-reviewed and independent funding for economic evaluations unfortunately leads to reliance on industry sponsorship in this field. In the future, we recommend that high-quality, prospective, cost-effectiveness analysis be planned alongside the intervention trials and that these be designed, conducted, analyzed, and reported independent of industry sponsors.

Key messages
============

• Low-molecular-weight heparins appear to be the most economically attractive strategy for venous thromboembolism prevention among the majority of medical and surgical patients, whereas fondaparinux is more economically attractive for orthopedic patients.

• However, approximately two thirds of all evaluations were directly funded by the manufacturer of the new drug.

• Such drugs were more likely to be found economically attractive in comparison to other strategies.

• Limited opportunity for peer-reviewed and independent funding for economic evaluations may lead to reliance on industry sponsorship and bias in this field.
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